Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

NCT00993239 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Birinapant (TL32711)

Sponsor

TetraLogic Pharmaceuticals